• A Sicras and J Rejas-Gutiérrez.
• Departamento de Planificación, Badalona Serveis Assistencials, Badalona, Barcelona. asicras@bsa.gs
• Rev Neurol. 2004 Aug 16; 39 (4): 312-6.

Introduction And ObjectiveLong term duration of treatment of the dementia of Alzheimer type, the most frequent type of dementia in our environment, is associated with delay in patient functional and cognitive impairment. The aim of the study was to determine retrospectively the persistence of treatment with donepezil, rivastigmine and galantamine in patients with dementia of the Alzheimer type in a population setting.Patients And MethodsRetrospective study performed in Primary Care Health Centres. The study included patients who were treated between January, 2000 and September, 2003. Kaplan-Meier survival analysis was applied to assess pattern of treatment persistence.ResultsA total of 95 patients (78.8% female), with a mean age of 77.6 years (SD: 6.2) were included; 39 donepezil, 35 rivastigmine, and 21 galantamine, with a mean MMSE score of 10.3 +/- 7.8, 9.7 +/- 8.4 and 13.6 +/- 7.1, respectively (p = 0.256). Mean treatment duration was donepezil: 80.3 (SD: 7.7) weeks, rivastigmine: 52.4 (SD: 5.3) weeks and galantamine: 49.8 (SE: 4.0) weeks, p < or = 0.01. Median persistence of treatment was 129.3 weeks for donepezil, 59.1 for rivastigmine and 45.0 for galantamine, p < or = 0.001 in both cases. At week 52, 62% of donepezil-treated patients maintained the initial therapy, compared with 40% rivastigmine-treated and 33% galantamine-treated, p < 0.05.ConclusionThis retrospective study found that patients with dementia of the Alzheimer type treated with donepezil showed more persistence of treatment compared which those who received rivastigmine or galantamine.

21 keywords...

hide…